News headlines about MedAssets (NASDAQ:MDAS) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MedAssets earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave press coverage about the technology company an impact score of 47.1541492709471 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

COPYRIGHT VIOLATION NOTICE: “MedAssets (MDAS) Receives Media Impact Rating of 0.06” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/08/medassets-mdas-receives-media-impact-rating-of-0-06.html.

About MedAssets

MedAssets, Inc (MedAssets) provides technology-enabled products and services to healthcare organizations, including hospitals, health systems, non-acute healthcare providers, payers, other service providers and product manufacturers. The Company operates its business through two business segments: Spend and Clinical Resource Management (SCM) and Revenue Cycle Management (RCM).

Insider Buying and Selling by Quarter for MedAssets (NASDAQ:MDAS)

Receive News & Stock Ratings for MedAssets Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedAssets Inc. and related stocks with our FREE daily email newsletter.